The University of Chicago has acquired technology and intellectual property rights for the development of amifostine, a drug researchers hope can prevent genetic changes caused by a variety of sources of ionizing radiation exposure, including common Computer Tomography (CT) scans.
Pinnacle Oncology LLC, a subsidiary of Pinnacle Biologics Inc., has announced an agreement with the University of Chicago acquire technology and intellectual property rights for the development of amifostine, a drug researchers hope can prevent genetic changes caused by a variety of sources of ionizing radiation exposure, including common Computer Tomography (CT) scans.
Amifostine was initially developed by the United States Army to protect military personnel from the toxic effects of radiation exposure in the event of a nuclear war. Pinnacle Oncology cites animal studies showing amifostine to be effective in protecting against genomic instability and associated long term genomic damages resulting from radiation exposure, such as from CT scans and other diagnostic radiology and radiation oncology procedures that lead to DNA damages, chromosomal aberrations and gene mutations, all of which are associated with cancer.
Pinnacle Biologics vice-chairman Viren Grover cited a National Cancer Institute study suggesting that the 70 million CT scans performed in the United States in 2007 may have contributed to 29,000 new cancers and 14,500 deaths.
Amifostine is FDA-approved to lessen side effects such as dry mouth in patients receiving chemotherapy, among other applications.
“In addition to protecting against genomic instability, somatic mutagenesis and carcinogenesis, amifostine may also facilitate protection against germ line mutations. These exposures can come from a variety of sources, including common diagnostic procedures such as CT scans and more generalized environmental exposures, as recently evidenced by the nuclear plant accident in Japan,” said David Grdina, professor of Radiation and Cellular Oncology at the University of Chicago and inventor of the technology behind the development of amifostine as a genomic stabilizing agent.
A Victory for Radiology: New CMS Proposal Would Provide Coverage of CT Colonography in 2025
July 12th 2024In newly issued proposals addressing changes to coverage for Medicare services in 2025, the Centers for Medicare and Medicaid Services (CMS) announced its intent to provide coverage of computed tomography colonography (CTC) for Medicare beneficiaries in 2025.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
ACR Collaborative Model Leads to 35 Percent Improvement with Mammography Positioning Criteria
July 1st 2024Noting significant variation with facilities for achieving passing criteria for mammography positioning, researchers found that structured interventions, ranging from weekly auditing of images taken by technologists to mechanisms for feedback from radiologists to technologists, led to significant improvements in a multicenter study.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.